Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will GSK quit on Nabi after PhIII nixes NicVax smoking cessation vaccine?

This article was originally published in Scrip

Executive Summary

Investors fled from shares of Nabi Biopharmaceuticals after the firm reported that its investigational nicotine vaccine, NicVax (nicotine conjugate immunotherapeutic), missed the primary endpoint in the first of two confirmatory Phase III trials. Its market capitalisation fell $180 million, as shares of the Rockville, Maryland-based firm fell by $3.74, or 66%, to close at $1.89 on 18 July. The results of the second trial are not expected until late this year or early 2012.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts